



Recombinant Human Interleukin-15 (IL-15)

PRODUCT ANALYSIS SHEET

Catalog Number:	PHC9155
Lot Number:	S022721B
Quantity:	25 µg
Molecular Weight:	13.2 kDa (114 amino acid residues)
Purity:	>98% as determined by SDS-PAGE analysis.
Biological Activity:	ED ₅₀ range: 0.1-0.5 ng/mL. The biological activity was determined by measuring the dose-dependent proliferation of mouse CTLL-2 cells. The optimal concentration for each specific application should be determined empirically by an initial dose-response assay. IL-15 stimulates the proliferation of T cells, and also involved in activation of NK cells, neutrophils, and macrophages. Enhanced IL-15 secretion is observed in several disease states, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and pulmonary inflammatory diseases.
Formulation:	Lyophilized, carrier free.
Sterility:	Filtered prior to lyophilization through a 0.22 micron sterile filter.
Endotoxin:	<0.1 ng/µg
Production:	Recombinant human IL-15 is produced in <i>E. coli</i> and purified by sequential chromatography.
Reconstitution Recommendation:	We recommend that the vial be briefly centrifuged prior to opening to bring the contents to the bottom. Lyophilized human IL-15 should be reconstituted in sterile, distilled water to a concentration of 0.1-1.0 mg/mL. For maximal stability, a carrier protein, such as 0.1-1.0% BSA, may be included. The reconstituted protein should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in low endotoxin medium or buffered solution with FBS or tissue culture grade BSA.
Suggested Working Dilutions:	The optimal concentration should be determined for each specific application.
Storage:	For maximal stability, store this lyophilized preparation at ≤ -20°C, preferably desiccated. For shipment and short term storage (up to 2 weeks), storage at 2-8°C is sufficient. Reconstituted human IL-15 should be stored at ≤ -20°C (not in a frost-free freezer). Keep freeze-thaw cycles to a minimum.
References:	Alpdogan, O, and van der Brink, M.R. (2005) IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 26(1):56-64. (review) McInnes, I.B. and Gracie, J.A. (2004) Interleukin-15: a new target for the treatment of inflammatory disease. Curr. Opin. Pharmacol. 4(4):392-397. (review)

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHC9155

(Rev 1.1) (DCC-08-1232)

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

